Johnson & Johnson says its lung cancer drug significantly extended survival

Taking stock of the drug industry, from the lab to the medicine chest

January 7, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Mario Tama/Getty Images STAT+ | Johnson & Johnson says its lung cancer drug significantly extended survival  The J&J bispecific antibody, paired with a Janssen drug, has the potential to become standard treatment for non-small lung cancer patients. By Angus Chen STAT+ | Four years after AlphaFold's AI 'solved' protein structure, a fierce competition lives on AlphaFold solved a structural biology riddle: predicting protein structure. But CASP, a global competition to solve that problem, lives on. By Brittany Trang STAT+ | Generic GLP-1 drugs could help Medicare drive a harder bargain for Ozempic and Wegovy Medicare is already spending billions on drugs like Ozempic, and Biden recently propsed expanding access to obesity treatments. By John Wilkerson Adobe Opinion: The long history of distrust for American insurance companies STAT First Opinion looks at how the complexity, fragmentation, and power of for-profit insurers make U.S. health care a recipe for suspicion and ill will. By Katherine Hempstead

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser